Virologic and immunologic response to highly active antiretroviral therapy.

Lisa Paula Jacobson, John P. Phair, Traci E. Yamashita

Research output: Contribution to journalArticle

Abstract

Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.

Original languageEnglish (US)
Pages (from-to)74-81
Number of pages8
JournalJoint Commission Journal on Quality and Patient Safety
Volume1
Issue number2
StatePublished - Jun 2004

Fingerprint

Highly Active Antiretroviral Therapy
HIV
CD4 Lymphocyte Count
Immune System
Acquired Immunodeficiency Syndrome
Cohort Studies
Biomarkers
RNA

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Virologic and immunologic response to highly active antiretroviral therapy. / Jacobson, Lisa Paula; Phair, John P.; Yamashita, Traci E.

In: Joint Commission Journal on Quality and Patient Safety, Vol. 1, No. 2, 06.2004, p. 74-81.

Research output: Contribution to journalArticle

@article{80a4699163b449249babea5b4b44c2cc,
title = "Virologic and immunologic response to highly active antiretroviral therapy.",
abstract = "Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.",
author = "Jacobson, {Lisa Paula} and Phair, {John P.} and Yamashita, {Traci E.}",
year = "2004",
month = "6",
language = "English (US)",
volume = "1",
pages = "74--81",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Virologic and immunologic response to highly active antiretroviral therapy.

AU - Jacobson, Lisa Paula

AU - Phair, John P.

AU - Yamashita, Traci E.

PY - 2004/6

Y1 - 2004/6

N2 - Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.

AB - Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.

UR - http://www.scopus.com/inward/record.url?scp=24144482810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144482810&partnerID=8YFLogxK

M3 - Article

C2 - 16091226

AN - SCOPUS:24144482810

VL - 1

SP - 74

EP - 81

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 2

ER -